Glucotrack, INC 8-K filings

GlucoTrack, Inc. announces a 1-for-20 reverse stock split and the successful completion of its first in-human clinical study for its continuous blood glucose monitor (CBGM).

Glucotrack, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective February 4, 2025, to meet Nasdaq's minimum bid price requirement.

Glucotrack, Inc. has appointed Peter C. Wulff as its new Chief Financial Officer, effective immediately, following the resignation of James Cardwell.

Glucotrack, Inc. has announced it received ISO 13485:2016 certification from the British Standards Institute, demonstrating its commitment to quality in the design and manufacturing of its continuous blood glucose monitor.

GlucoTrack files an amendment to its previous 8-K report to correct a scrivener's error regarding the number of shares issuable upon exchange of Series B Warrants.

GlucoTrack, Inc. reports the issuance of 134,785,015 shares of common stock following the exchange of Series B Warrants.

Glucotrack, Inc. will present an update on its continuous blood glucose monitor at the TechBio Showcase 2025.

Glucotrack Inc. stockholders approved an increase in authorized shares and a reverse stock split at a special meeting on January 3, 2025.

GlucoTrack, Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, triggering a 180-day compliance period.

GlucoTrack, Inc. has entered into an agreement to sell up to $8.23 million of its common stock through an at-the-market offering program.

Glucotrack has initiated patient enrollment for a short-term human clinical study of its continuous blood glucose monitor, which measures glucose directly from blood.

Glucotrack, Inc. closed a public offering and concurrent private placement, raising approximately $9.1 million and securing shareholder support for key proposals including a reverse stock split.

Glucotrack, Inc. has successfully closed a $10 million public offering and a concurrent private placement converting $4 million in debt, aiming to bolster its working capital and general corporate activities.

Glucotrack, Inc. has announced a public offering of approximately 7.195 million shares of common stock, expected to raise $10 million, along with a concurrent private placement to convert $4 million in debt to equity.

Glucotrack, Inc. will present its continuous blood glucose monitor at the 2024 BioFuture Conference, highlighting its long-term implantable technology.

Glucotrack will present updated preclinical data for its continuous blood glucose monitor at the 2024 Diabetes Technology Meeting.

GlucoTrack, Inc. stockholders approved the issuance of shares related to a note and warrants at a special meeting held on September 24, 2024.

GlucoTrack, Inc. converted approximately $259,300 of debt into common stock and issued warrants to an investor on September 5, 2024.

Glucotrack, Inc. has appointed Paul V. Goode and John Ballantyne to its Board of Directors, effective August 27, 2024, with Mr. Ballantyne's appointment announced in a press release on September 3, 2024.

Glucotrack, Inc. has announced the appointment of Sandie Martha as Vice President of Clinical Operations, bringing extensive experience in clinical trials to the company.

A recent market research study indicates that over 50% of surveyed diabetes patients are open to adopting Glucotrack's new continuous blood glucose monitor concept.

Glucotrack, Inc. will present market research data on their continuous blood glucose monitor concept at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference.

Glucotrack, Inc. has secured $4 million in funding through a convertible promissory note and warrants to advance the development of its continuous blood glucose monitor.

Glucotrack, Inc. has entered into a private placement of convertible promissory notes, raising $350,000 from investors.

GlucoTrack Inc. distributed a slide presentation on July 8, 2024, as a shareholder update.

Glucotrack, Inc. has entered into a private placement agreement, raising $100,000 through the issuance of unsecured promissory notes and warrants.

Glucotrack, Inc. has appointed Andy Balo, a seasoned medical technology executive, to its Board of Directors and amended its bylaws to reduce the quorum requirement for shareholder meetings.

Glucotrack's implantable continuous glucose monitor successfully completed a 60-day preclinical study, demonstrating the feasibility of glucose monitoring in the epidural space.

GlucoTrack, Inc. is facing potential delisting from the Nasdaq Stock Market after failing to meet minimum bid price and stockholders' equity requirements, and has requested a hearing to appeal the decision.

GlucoTrack, Inc. has completed a 1-for-5 reverse stock split, reducing its outstanding shares from approximately 27.4 million to 5.5 million, effective May 17, 2024.